Trial Profile

A Single-Site, Investigator-Initiated Study to Evaluate Time in Range in Subjects With Type 2 Diabetes Mellitus Using Mealtime Inhaled Insulin (Afrezza) Plus Basal Insulin Compared to Multiple Daily Injections

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 06 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Jun 2020 According to a MannKind Corporation media release, data from this study will be presented at the American Diabetes Association 80th Scientific Sessions during the ePoster session (Poster 990) on Saturday, June 13, 2020.
13 Jun 2020 Results published in the MannKind Corporation Media Release
28 Jan 2020 Planned End Date changed from 1 Mar 2020 to 15 Mar 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com